In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine.

@article{Xu1996InVI,
  title={In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine.},
  author={Z H Xu and Hong-Guang Xie and Hong-Hao Zhou},
  journal={British journal of clinical pharmacology},
  year={1996},
  volume={42 4},
  pages={518-21}
}
Studies were performed in eight healthy extensive metabolizers of mephenytoin and debrisoquine to determine the effect of fluvoxamine on the activities of S-mephenytoin 4'-hydroxylase (CYP2C19) and metoprolol alpha-hydroxylase (CYP2D6). Therapeutic dosing with fluvoxamine (100 mg day-1) for 2 weeks caused a significant increase in the 0-8 h urinary S/R ratio of mephenytoin from 0.16 to 0.55 (95% confidence interval for difference between means: 0.28-0.50; P < 0.01), accompanied by a 54… CONTINUE READING